Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation,British Journal of Pharmacology

当前位置： X-MOL 学术 › Br. J. Pharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Inhibition of the sodium–glucose co‐transporter SGLT2 by canagliflozin ameliorates diet‐induced obesity by increasing intra‐adipose sympathetic innervation
British Journal of Pharmacology ( IF 6.8 ) Pub Date : 2021-01-22 , DOI: 10.1111/bph.15381
Xuping Yang _{1,

2,

3} , Qinhui Liu ₃ , Yanping Li ₃ , Yi Ding ₄ , Yan Zhao ₅ , Qin Tang _{1,

3} , Tong Wu _{1,

3} , Lei Chen _{1,

3} , Shiyun Pu _{1,

3} , Shihai Cheng _{1,

3} , Jinhang Zhang _{1,

3} , Zijing Zhang _{1,

3} , Ya Huang _{1,

3} , Rui Li _{1,

3} , Yingnan Zhao _{1,

3} , Min Zou ₁ , Xiongjie Shi ₄ , Wei Jiang ₆ , Rui Wang ₇ , Jinhan He _{1,

3}

Affiliation

Inhibition of the sodium–glucose cotransporter 2 (SGLT2) induces hypoglycaemia by increasing urinary glucose excretion and increasing the use of fat. However, the underlying mechanism is poorly understood. This study was aimed to determine the effects of canagliflozin, a selective SGLT2 inhibitor, on diet‐induced obesity and the underlying mechanism(s).

中文翻译：

canagliflozin对钠-葡萄糖共转运蛋白SGLT2的抑制作用通过增加脂肪内交感神经来改善饮食引起的肥胖。

钠-葡萄糖共转运蛋白2（SGLT2）的抑制通过增加尿中葡萄糖的排泄和增加脂肪的使用而引起低血糖症。但是，人们对这种潜在的机制知之甚少。这项研究的目的是确定选择性SGLT2抑制剂canagliflozin对饮食引起的肥胖症及其潜在机制的影响。

更新日期：2021-03-21

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11